Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1215 - Cisplatin in NIPEC or HIPEC?

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Ivan Alvovsky

Citation

Annals of Oncology (2018) 29 (suppl_8): viii1-viii13. 10.1093/annonc/mdy268

Authors

I.K. Alvovsky, V.G. Bespalov, G.S. Kireeva

Author affiliations

  • Scientific Laboratory Of Cancer Chemoprevention And Oncopharmacology, N.N. Petrov National Medical Research Center of Oncology, 197758 - Saint-Petersburg/RU
More

Resources

Abstract 1215

Background

Eliminating minimal residual disease in patients with advanced ovarian cancer (AOC) is necessary to prevent recurrencies and could be achieved with hyperthermic intraperitoneal chemoperfusion (HIPEC). Cisplatin comprises the majority of HIPEC regimens due to its known synergic efficacy with hyperthermia. However, emerging report are impugning its role. Our goal was to compare the survival of rats treated with cisplatin by hyperthermic and normothermic intraperitoneal chemoperfusion (HIPEC and NIPEC) and to evaluate, whether the outcome of HIPEC would depend on its opened (oHIPEC) or closed (cHIPEC) delivery.

Methods

A rodent model of ascitic ovarian cancer was used. 1*107 tumor cells were inoculated i.p. 48 hours prior to the treatment to 48 female Wistar rats. As indicated by our previous research, this time limit of tumor progression reflects the biological pattern of optimally debulked AOC in women. Each 12 rats were randomized into four groups to receive either cisplatin at a maximum tolerated dose of 20 mg/kg in NIPEC, cHIPEC, and oHIPEC or i.p. 20 mg/kg saline as a control without treatment.

Results

The mean survival in the untreated control was 31.8 days. Cisplatin in NIPEC increased the mean survival by 22 days (P = 0.0007), while in cHIPEC and oHIPEC by 19.9 (P = 0.003) and 31.5 (P = 0.003) days, respectively. Cisplatin in oHIPEC was shown to be the most effective combination. The differences between NIPEC and cHIPEC with cisplatin were not statistically significant.

Conclusions

Our results prompt that NIPEC with cisplatin might be just as effective as cHIPEC in increasing survival in AOC.

Clinical trial identification

Legal entity responsible for the study

Vladimir Bespalov.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings